Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BIOA
stocks logo

BIOA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast BIOA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIOA is 10.00 USD with a low forecast of 5.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast BIOA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIOA is 10.00 USD with a low forecast of 5.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
1 Sell
Hold
Current: 10.500
sliders
Low
5.00
Averages
10.00
High
15.00
Current: 10.500
sliders
Low
5.00
Averages
10.00
High
15.00
Citi
Buy
upgrade
$10 -> $15
2025-10-29
Reason
Citi
Price Target
$10 -> $15
2025-10-29
upgrade
Buy
Reason
Citi raised the firm's price target on BioAge Labs to $15 from $10 and keeps a Buy rating on the shares. The firm adjusted biotech price targets as part of a Q3 earnings preview.
Citi
Neutral -> Buy
upgrade
$5 -> $10
2025-10-22
Reason
Citi
Price Target
$5 -> $10
2025-10-22
upgrade
Neutral -> Buy
Reason
Citi upgraded BioAge Labs to Buy from Neutral with a price target of $10, up from $5. The firm believes the company's BGE-102 can become a "differentiated" NLRP3 inhibitor in treating obesity.
Citi
Samantha Semenkow
Neutral -> Buy
upgrade
$5 -> $10
2025-10-22
Reason
Citi
Samantha Semenkow
Price Target
$5 -> $10
2025-10-22
upgrade
Neutral -> Buy
Reason
Citi analyst Samantha Semenkow upgraded BioAge Labs to Buy from Neutral with a price target of $10, up from $5. The firm believes the company's BGE-102, an oral NLRP3 inhibitor being developed for obesity, could be "differentiating." BGE-102 is a "potentially differentiated" NLRP3 inhibitor that could be given in combination with oral GLP1s or be a monotherapy, the analyst tells investors in a research note.
Citigroup
Samantha Semenkow
Hold
Maintains
$7 → $5
2025-03-24
Reason
Citigroup
Samantha Semenkow
Price Target
$7 → $5
2025-03-24
Maintains
Hold
Reason
Morgan Stanley
Jeffrey Hung
Sell
Initiates
$5
2025-03-07
Reason
Morgan Stanley
Jeffrey Hung
Price Target
$5
2025-03-07
Initiates
Sell
Reason
Morgan Stanley assumed coverage of BioAge Labs with an Underweight rating and $5 price target following the recent pipeline setback resulting in the discontinuation of lead program azeleprag. While the firm believes the pipeline may have potential, development remains in the early stages and Morgan Stanley awaits greater clarity.
William Blair
Andy Hsieh
Hold
Initiates
n/a
2025-02-28
Reason
William Blair
Andy Hsieh
Price Target
n/a
2025-02-28
Initiates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for BIOAGE Labs Inc (BIOA.O) is -3.89, compared to its 5-year average forward P/E of -2.87. For a more detailed relative valuation and DCF analysis to assess BIOAGE Labs Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.87
Current PE
-3.89
Overvalued PE
-0.83
Undervalued PE
-4.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.30
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.27
Undervalued EV/EBITDA
-2.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
30.12
Current PS
0.00
Overvalued PS
56.01
Undervalued PS
4.22
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BIOA News & Events

Events Timeline

(ET)
2025-12-04
09:10:00
BioAge Labs Reports Positive Interim Data for BGE-102 Clinical Trial
select
2025-08-15 (ET)
2025-08-15
09:08:31
BioAge Labs announces first participant dosed in Phase 1 trial of BGE-102
select
2025-06-22 (ET)
2025-06-22
16:44:19
BioAge Labs announces it will present new preclinical data on APJ agonism
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04PRnewswire
PinnedBioArctic and Eisai Present Lecanemab Findings Indicating Up to 8.3-Year Delay in Alzheimer's Progression
  • Treatment Delay Effect: At the CTAD conference in San Diego, Eisai presented findings indicating that continued treatment with Lecanemab could delay progression from Mild Cognitive Impairment (MCI) to Moderate Alzheimer's Disease (AD) by up to 8.3 years, highlighting the significance of early intervention.
  • New Formulation Approval: The subcutaneous formulation of Lecanemab (SC-AI) received approval for maintenance treatment in the U.S. in August 2025, and the rolling supplemental Biologics License Application (sBLA) for initiation treatment was completed in November 2025, providing patients with a more convenient treatment option.
  • Clinical Data Support: Real-world data presented at the congress demonstrated continued clinical benefits from Lecanemab treatment, with a safety profile consistent with the Phase 3 Clarity AD study, further enhancing its competitive position in the market.
  • Long-term Partnership: BioArctic's collaboration with Eisai, established in 2005, has led to the successful development of Lecanemab, which not only offers hope for Alzheimer's patients but also lays a solid foundation for joint commercialization in the global market.
[object Object]
Preview
9.5
12-04Benzinga
Donaldson Reports Positive Results and Teams Up with Science Applications International, Descartes Systems, Dollar General, and Other Major Stocks Rising on Thursday

  • U.S. Stock Market Performance: U.S. stocks declined slightly, with the Dow Jones falling about 0.1% on Thursday, while several companies reported strong earnings and raised their guidance.

  • Donaldson Company Earnings: Donaldson Company, Inc. saw a 4.7% increase in its stock price after reporting a 3.9% year-over-year sales growth and raising its fiscal 2026 adjusted EPS guidance.

  • Notable Stock Gains: UiPath Inc. and Science Applications International Corporation experienced significant stock price increases of 16.5% and 15.8%, respectively, following better-than-expected financial results and raised guidance.

  • Other Companies with Gains: Several other companies, including ASP Isotopes Inc. and BioAge Labs, also saw notable stock price increases due to positive financial news and analyst ratings.

[object Object]
Preview
9.0
12-04Globenewswire
BioAge Reports Positive Interim Data for BGE-102 Phase 1 Trial
  • Good Tolerability: BGE-102 demonstrated excellent tolerability across all doses (10, 30, 60, and 120 mg) in the Phase 1 trial, with mild adverse events that resolved without intervention, indicating strong safety and potential market viability for the drug.
  • Significant Target Engagement: The drug achieved 90% to 98% suppression of IL-1β by Day 14, showcasing its effectiveness in addressing cardiovascular risk factors, which may lay the groundwork for future product commercialization.
  • High Brain Penetration: Doses of 60 mg and above exceeded IC90 levels in cerebrospinal fluid after 14 days, demonstrating the ability to target inflammation in both the central nervous system and peripheral tissues, enhancing its competitive edge in the market.
  • Trial Expansion Plans: BioAge is set to complete the multiple ascending dose trial in obese participants by the first half of 2026, which is expected to provide early biomarker proof-of-concept for treating cardiovascular risk factors, further advancing the company's position in the biopharmaceutical sector.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is BIOAGE Labs Inc (BIOA) stock price today?

The current price of BIOA is 10.5 USD — it has increased 13.88 % in the last trading day.

arrow icon

What is BIOAGE Labs Inc (BIOA)'s business?

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.

arrow icon

What is the price predicton of BIOA Stock?

Wall Street analysts forecast BIOA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIOA is 10.00 USD with a low forecast of 5.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is BIOAGE Labs Inc (BIOA)'s revenue for the last quarter?

BIOAGE Labs Inc revenue for the last quarter amounts to 2.05M USD, decreased % YoY.

arrow icon

What is BIOAGE Labs Inc (BIOA)'s earnings per share (EPS) for the last quarter?

BIOAGE Labs Inc. EPS for the last quarter amounts to -0.56 USD, decreased -18.84 % YoY.

arrow icon

What changes have occurred in the market's expectations for BIOAGE Labs Inc (BIOA)'s fundamentals?

The market is revising Upward the revenue expectations for BioAge Labs, Inc. (BIOA) for FY2025, with the revenue forecasts being adjusted by 37.92% over the past three months. During the same period, the stock price has changed by 120.59%.
arrow icon

How many employees does BIOAGE Labs Inc (BIOA). have?

BIOAGE Labs Inc (BIOA) has 62 emplpoyees as of December 05 2025.

arrow icon

What is BIOAGE Labs Inc (BIOA) market cap?

Today BIOA has the market capitalization of 376.48M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free